Skip to content
Biosion
  • About
    • Executive Team
    • Development Team
    • Advisory Board
    • Careers
  • Platform
    • H3 Antibody Technology
    • SynTracer™ Internalization Platform
    • FlexibodyTM Bispecific Platform
  • Pipeline
  • Partners
  • News
  • Contact
  • English
  • 中文
  • About
    • Executive Team
    • Development Team
    • Advisory Board
    • Careers
  • Platform
    • H3 Antibody Technology
    • SynTracer™ Internalization Platform
    • FlexibodyTM Bispecific Platform
  • Pipeline
  • Partners
  • News
  • Contact
  • English
  • 中文

Careers

Join Our Team and Grow With Us

At Biosion, we are innovators, leaders, and collaborators. We love what we do and who we work with. And at the heart of everything we do is an intense desire to innovate for cures and to improve quality of life.

Job opportunities

Humanized Anti-ST2 Antibody BSI-056T used for the treatment of asthma

Partnering objectives
Seeking a collaborative licensing opportunity with a company that has a strategic interest in the treatment of asthma, atopic dermatitis and chronic obstructive pulmonary disease.

Field: Treatment of asthma, atopic dermatitis and chronic obstructive pulmonary disease.

Technology and MOA
MOA:ST2 antagonist, a humanized anti-ST2 antibody inhibits binding of IL-33 to the ST2.

IL-33 and ST2 play important roles in allergic bronchial asthma. IL-33 contribute to the induction and maintenance of eosinophilic inflammation in the airways by acting on lung fibroblasts by binding to its ST2 receptor. ST2 is a member of the interleukin-1 receptor family and exists in a transmembrane (ST2L) and a soluble form (sST2) due to alternative splicing. Unregulated IL-33 activity leads to activation of T-helper type 2 cells, mast cells, dendritic cells, eosinophils and basophils, ultimately leading to increased expression of cytokines and chemokines.  The drug candidate BSI-056T targets the ST2 and inhibits its binding to the IL33 thereby alleviates the condition.

Marketing opportunity
The binding of IL-33 to the ST2 receptor activates inflammatory cells through the nuclear factor-κB and mitogen-activated protein kinases pathways and induces the expression of Th2-type cytokines.

Excessive stimulation of ST2/IL-33 was associated with autoimmune diseases, including arthritis, allergic inflammation, and airway hyperactivity, pointing to a significant function of ST2 in the pathogenesis of inflammation-related diseases. And studies have shown that blockage of IL-33 signaling by a soluble ST2 protein or anti-ST2 mAb inhibits the immune response of asthma in mice.

The global market for asthma should reach $21.1 bn in 2025.
RG-6149’s net present value is estimated about 100 million USD by GlobalData

Differentiable treatment with potential to be first/ best in class
BSI-056T demonstrates a higher affinity and better in vitro bioactivity than RG-6149 (AMG-282, Amgen Inc.), which is currently in phase-II clinical trial

Indications
• Asthma
• Atopic Dermatitis
• Allergic inflammation
• Airway hyperactivity

Data
Key parameters of humanized anti-ST2 antibody BSI-056T as compared to RG-6149:
• Exhibits comparable affinity as compared to RG-6149
• Shows more potent in vitro efficacy
• Shows overlapped epitope to RG-6149
• In vivo efficacy and PK/PD studies on-going
• Cell-line development and CMC are on-going and is expected to file IND in Q3 of 2021

Intellectual property
For discussion under CDA.

Committed to bring next generation innovative therapeutics to treat immune and oncologic diseases.

LinkedIn

CHINA

BIOSION, INC.

5th Floor, Building D
3-1 Zhongdan Unit
South Longshan Rd
Jiangbei New District
Nanjing, Jiangsu, China 210061
Tel: (86) 025-5829-1977

USA

BIOSION USA, INC.

1 Innovation Way, Suite 300
Newark, DE 19711
Tel: 1-302-998-5126

Australia

BIOSION AUSTRALIA PTY LTD.

58 Gipps Street
Collingwood, Victoria 3066
Tel: 1-302-998-5126

Website by Bartlett Interactive
Terms Privacy
© 2022. All rights reserved.
Close Bitnami banner
Bitnami